Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors.

3005Background: SHP2 transduces signals from activated receptor tyrosine kinases to downstream pathways including MAPK. TNO155 is a selective, allosteric, oral inhibitor of SHP2. Methods: CTNO155X2...